Patrick Kevin Kane, Corporate Controller of Insmed Inc, filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on November 3, 2026, disclosing holdings as of the event date of October 30, 2026.

Key Highlights

  • Reporting person: Patrick Kevin Kane, identified as Corporate Controller of Insmed Inc (NASDAQ:INSM).
  • Direct common stock holdings: 9,921 shares beneficially owned directly, including Restricted Stock Units (RSUs) granted under the company's Amended and Restated 2019 Incentive Plan.
  • RSU breakdown: 2,258 RSUs vest 25% on each anniversary of the grant date through the fourth anniversary; 5,246 RSUs vest 25% on the first day of the first month following the first anniversary of the grant, then 25% on each subsequent anniversary.
  • Stock options disclosed: Nine tranches of stock options (right to buy) covering a total of 26,547 shares of common stock, with exercise prices ranging from $17.07 to $177.12, all held directly.
  • Event date: October 30, 2026, is stated as the date of the event requiring the filing.
  • Signing authority: The form was signed by Michael A. Smith as attorney-in-fact for Patrick Kane, pursuant to a Power of Attorney listed as Exhibit 24.

Kane's Initial Beneficial Ownership at Insmed: Common Stock and Option Details

According to the filing, Kane directly beneficially owns 9,921 shares of Insmed common stock. The filing notes this figure includes RSUs representing a contingent right to receive one share of common stock each, granted under the company's Amended and Restated 2019 Incentive Plan, as amended. Two distinct RSU vesting schedules apply: 2,258 RSUs vest 25% on each anniversary of the grant date through the fourth anniversary, while 5,246 RSUs vest 25% on the first day of the first month following the first anniversary of the grant date, then 25% on each subsequent anniversary of that initial vesting date until fully vested.

The filing also discloses nine tranches of stock options, all held directly. Seven of these options have expiration dates ranging from January 5, 2033 to January 2, 2036, with exercise prices of $177.12, $67.22, $65.72, $25.83, $29.13, $18.95, and $19.74. The filing notes that two of these tranches vest 25% on the Initial Vesting Date with an additional 12.5% vesting every six months thereafter, while two other tranches vest 25% on the first anniversary of the grant date with an additional 12.5% on each six-month anniversary until fully vested. Two additional options with expiration dates of May 11, 2032 and January 6, 2032 carry exercise prices of $17.07 and $26.43, covering 2,914 and 643 shares respectively, and have exercisable dates of May 11, 2026 and January 6, 2026 as stated in the filing.

All securities reported are held in direct ownership form. No indirect beneficial ownership was reported in either Table I or Table II of the filing.

What Was Disclosed

Insmed Inc Corporate Controller Patrick Kevin Kane submitted an initial beneficial ownership statement reflecting holdings as of October 30, 2026, covering 9,921 directly held common shares (including RSUs) and nine tranches of directly held stock options across various exercise prices and expiration dates.